期刊
CURRENT DRUG SAFETY
卷 8, 期 5, 页码 357-363出版社
BENTHAM SCIENCE PUBL
DOI: 10.2174/15680266113136660069
关键词
Breast cancer; metformin; mortality; survival; type 2 diabetes mellitus
资金
- CARING project (European Community's Seventh Framework Program [282526]
- CARING project (European Community's Seventh Framework Program) [282526]
- MSD
- Eli Lilly and Servier
- Sanofi Aventis public-private partnerships, e.g. IMI, TI Pharma
- Netherlands Organisation for Health Research and Development (ZonMW)
- Dutch Health Care Insurance Board (CVZ)
- EU 7th Framework Program (FP7)
- Dutch Medicines Evaluation Board (MEB)
- Dutch Ministry of Health
- Royal Dutch Pharmacists Association (KNMP)
- EU Innovative Medicines Initiative (IMI)
- Dutch Ministry of Health and industry (including GlaxoSmithKline, Pfizer, others)
Objective: This study was set out to determine whether metformin use influences survival in breast cancer patients treated with antidiabetic drugs as compared to non-users. Research Design and Methods: We used data from the Danish national registries (1996-2008) to identify adult female patients diagnosed with breast cancer who were prescribed antidiabetic medication. We performed multivariate Cox-proportional hazard regression to assess all-cause and breast cancer-specific mortality risks associated with metformin exposure. In a secondary analysis, we stratified use of metformin according to the cumulative number of prescriptions. Results: Of the 1058 breast cancer patients 349 died during follow-up, with breast cancer listed as the primary cause of death for 152 cases. Compared to non-use, current metformin treatment was associated with a significant reduction in overall mortality (adjusted HR 0.74, 95% CI, 0.58-0.96). For breast cancer-specific mortality, a non-significant risk reduction (adjusted HR 0.88, 95% CI, 0.59-1.29) was observed, which became significant after stratification according to cumulative number of prescriptions. An increased risk of both overall and breast cancer-specific mortality was observed in the first 12 months after discontinuation of metformin. Conclusions: We observed a nonsignificant reduction in breast cancer-specific mortality associated with metformin exposure among breast cancer patients treated with antidiabetic drugs. However, our findings suggest that long-term metformin use may have a beneficial effect on survival in patients with breast cancer. Further confirmation of these findings is needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据